Hematology

Hematologists have developed a framework of the core symptoms caregivers should look out for when caring for a patient who has just received CAR T-cell therapy.

The primary overall survival analysis of the phase 3 ZUMA-7 trial favors axicabtagene ciloleucel over standard of care therapy.

Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.

Patients with multiple myeloma who received subcutaneous daratumumab experienced reduced clinic times compared with those who received the agent intravenously.

Siltuximab led to the complete resolution of cytokine release syndrome in 5 out of 6 patients, with a median time to complete response within 1 hour.

Linh Nguyen BSN, RN, OCN, BMTCN, highlights the benefits of prospective toxicity data collection for patients undergoing bone marrow transplantation.

Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.

During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.

After 6 months of treatment with ruxolitinib, patients with polycythemia vera experienced a significant reduction in hematocrit levels compared with baseline.

Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.

At the 2023 Tandem Meeting, Jennifer Peterson, MS, RN, OCN, BMTCN, discussed how her institution implemented a successful outpatient CAR T-cell therapy program.

Pure essential oils reduced the severity of chemotherapy-induced nausea and vomiting in patients receiving autologous blood and marrow transplants.

Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia, lymphoma, and multiple myeloma.

Patients with relapsed or refractory multiple myeloma experienced improved progression-free survival with idecabtagene vicleucel. Notably, cytokine release syndrome rates were high with this treatment.

Elranatamab, an investigational BCMA/CD3-targeted bispecific antibody, has received priority review status for patients with relapsed or refractory multiple myeloma.

Restricted diets are commonplace at many cancer centers, but there is no evidence that they reduce a patient’s risk of infection.

Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.

As the therapy continues to evolve, best nursing practices become more nuanced.

At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.

First-line ibrutinib plus prednisone missed the primary endpoint in the phase 3 iNTEGRATE trial by not improving the response rate in patients with chronic graft-versus-host-disease compared with placebo plus prednisone.

Although most patients in the real-world setting would not have met the clinical trial eligibility criteria, the efficacy and safety outcomes with idecabtagene vicleucel were similar for both sets of patients with multiple myeloma.

Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.

Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.

The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.

Moxetumomab pasudotox-tdfk, a treatment for patients with relapsed/refractory hairy cell leukemia, will be permanently discontinued.

Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.

Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.

Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.